Eli Lilly Launches a New Migraine Drug
Eli Lilly (NYSE: LLY) launched its new pill for the acute treatment of migraines Friday after the Drug Enforcement Administration completed its review of the drug and classified it as having a low potential for abuse or dependence. Reyvow is the first drug of a new class, and treats not only pain, but sensitivity to light, sensitivity to sound, and nausea. It's the first new type of acute migraine drug to come to market in more than two decades.
Reyvow was approved by the Food and Drug Administration in October, but a DEA review was required because it acts on the central nervous system. Now that it has received a favorable decision on the scheduling of the drug, Lilly said it will be available for prescription immediately and will be in pharmacies in the next few days.
Image source: Getty Images.
Source Fool.com
